---
title: "Intuitive Surgical is 35% off its high as a court, J&J and Medtronic test its robot monopoly"
description: "A revived antitrust case, two newly cleared rivals and a return to the cardiac market it walked away from in 1998 all converge on the October 20 report. Hospitals pay the instrument-and-service lock-in; ISRG shareholders are carrying the de-rate."
publisher: "The Inference"
section: "Health"
published: 2026-10-05T18:32:14.752Z
modified: 2026-10-05T18:32:14.752Z
canonical: https://theinference.org/article/three-fronts-one-earnings-date-intuitive-s-robot-monopoly-gets-tested
language: en
keywords: "Intuitive Surgical, Medical Robots, Antitrust, Medtech, Earnings"
---

# Intuitive Surgical is 35% off its high as a court, J&J and Medtronic test its robot monopoly

> A revived antitrust case, two newly cleared rivals and a return to the cardiac market it walked away from in 1998 all converge on the October 20 report. Hospitals pay the instrument-and-service lock-in; ISRG shareholders are carrying the de-rate.

## A 35% de-rate on a 19% grower

[Intuitive](https://theinference.org/markets/companies/intuitive-surgical) closed at $391.95 on October 2, down 2.32% on the day and about 35% below its 52-week high of $603.88, valuing the company at $138.5 billion [1]. The business underneath is not shrinking: [second-quarter revenue rose 19% to $2.89 billion](https://www.nasdaq.com/press-release/intuitive-announces-second-quarter-earnings-2026-07-16) and net income reached $818 million [2]. What the tape is repricing is the durability of an annuity that has gone essentially unchallenged for nearly 25 years [3].

## The court reopened the blades aftermarket

On August 17 the Ninth Circuit [revived Surgical Instrument Service's claims](https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/intuitive-surgical-insider-selling-a-legal-setback-and-the-weight-loss-drug-question/69987769) that Intuitive blocked third parties from refurbishing da Vinci instruments, refusing to apply the usual Kodak standard because near-100% market power changes how the aftermarket is judged [4]. Intuitive [petitioned the full court on September 29](https://www.law360.com/healthcare-authority/articles/2531319/surgical-robot-co-says-9th-circ-expands-antitrust-law); the case, 25-1372, dates to March 2025 [5]. If refurbishing opens, hospitals get a cheaper second source for the highest-margin line, and the refurbisher gets the business.

## The installed base is contestable for the first time

[Johnson & Johnson](https://theinference.org/markets/companies/johnson-johnson)'s Ottava won De Novo authorization in July covering 10 general-surgery procedures, on a footprint 30-50% smaller than cart- and boom-mounted systems [3]. [Medtronic](https://theinference.org/markets/companies/medtronic)'s Hugo cleared the FDA for urology on December 3, 2025, with gynecology submissions advancing [6]. Da Vinci still holds clearances across urology, gynecology and general surgery [6].

## Cardiac is the offense as US growth slows

Intuitive was founded to chase robotic heart surgery and ran its first cardiac procedures in France and Germany in 1998, then spent decades on prostate and hernia volume instead [7][8]. It is going back: a US cardiac clearance in January and a [September 29 CE mark covering coronary bypass on da Vinci 5](https://www.massdevice.com/intuitive-receives-ce-mark-da-vinci-5-cardiac-heart-surgery-procedures/) [7][8]. The need is showing; US procedure growth slowed to 12% in the second quarter from 14% in the first, while international grew 20% [1].

*Chart: **US procedure growth slowed to 12% as international ran at 20%** Column chart of da Vinci procedure growth: US 14% in the first quarter of 2026, 12% in the second, international 20% in the second quarter.*

*Year-over-year da Vinci procedure growth as reported: US slowed from 14% in the first quarter to 12% in the second, while international procedures grew 20%. Sources: [1]. [1]*

## 76 cents of every revenue dollar arrives after install

The installed base reached 11,710 systems, up 12%, on 468 placements [2]. Instruments and accessories brought in $1.73 billion and services $472 million: 76 cents of every revenue dollar arrives after the robot is already installed [2]. Non-GAAP gross margin ran at 70.0% [2].

*Chart: **Instruments and services are 76% of Intuitive's quarterly revenue** Pie chart of Intuitive Surgical's second-quarter 2026 revenue: instruments and accessories $1,730M, services $472M, systems and other $688M.*

*Second-quarter 2026 revenue of $2.89 billion as reported: instruments and accessories ($1.73 billion) plus services ($472 million) are the installed-base annuity; systems and other is the balance. Sources: [2]. [2]*

## Guidance held, and every broker target sits above the tape

Guidance held at 13.5% to 15.5%, toward the midpoint [2]. A beat without a raise forecasts a slower second half, and targets were cut [9]. A fourth pressure is demand-side: GLP-1 drugs are absorbing the bariatric patient pool [4]. [RBC set $575 on October 1](https://www.ad-hoc-news.de/boerse/news/corporate-news/intuitive-surgical-stock-falls-2-32-percent-before-q3-report/70223590), $183 above the tape [1]; Piper Sandler called the decline unjustified at $470, UBS holds $500 and Bernstein trimmed to $685 [4].

*Chart: **Every listed broker target sits $78 to $293 above the October 2 close** Bar chart of four analyst price targets on Intuitive Surgical, from Piper Sandler's $470 to Bernstein's $685, all above a reference line marking the $391.95 close of October 2, 2026.*

*Published analyst price targets for ISRG: Piper Sandler, UBS and Bernstein as of August 21, 2026, RBC as of October 1, 2026. Reference line is the Nasdaq closing price of $391.95 on October 2, 2026. Sources: [1], [4]. [1][4]*

## Nothing filed yet shows erosion

The appeals court revived the claims without deciding them, and no filed number yet shows margin loss or lost placements [4][5]. Even J&J's own bull case calls Ottava "still early" [10]; the pessimist case assumes it scales slowly enough to lag MedTech margins [10]. Hugo starts from a single specialty [6].

## Three numbers settle it on October 20

Placements, US procedure growth, and instruments revenue per procedure [1][2]. The en banc answer arrives more slowly, and nothing filed yet prices what an open refurbishing market would cost the blades.

## Takeaway

Placements, US procedure growth and instruments revenue settle the quarter on October 20; the filed numbers show no erosion, but the Ninth Circuit case, Ottava and Hugo give the 35% de-rate real grounds.

## Sources

1. [ad-hoc-news, "Intuitive Surgical stock falls 2.32 percent before Q3 report", 5 October 2026](https://www.ad-hoc-news.de/boerse/news/corporate-news/intuitive-surgical-stock-falls-2-32-percent-before-q3-report/70223590)
2. [Intuitive via GlobeNewswire on Nasdaq, "Intuitive Announces Second Quarter Earnings", 16 July 2026](https://www.nasdaq.com/press-release/intuitive-announces-second-quarter-earnings-2026-07-16)
3. [MD+DI (Omar Ford), "How the Design of Johnson & Johnson's Ottava Saves Space in the Operating Room", 28 September 2026](https://www.mddionline.com/robotics/how-the-design-of-johnson-johnson-s-ottava-saves-space-in-the-operating-room)
4. [ad-hoc-news, "Intuitive Surgical: Insider Selling, a Legal Setback, and the Weight-Loss Drug Question", 23 August 2026](https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/intuitive-surgical-insider-selling-a-legal-setback-and-the-weight-loss-drug-question/69987769)
5. [Law360 (Bryan Koenig), "Surgical Robot Co. Says 9th Circ. 'Expands' Antitrust Law", 29 September 2026](https://www.law360.com/healthcare-authority/articles/2531319/surgical-robot-co-says-9th-circ-expands-antitrust-law)
6. [Morning Overview via MSN, "Medtronic is seeking US clearance to use its Hugo surgical robot in far more operations", 28 June 2026](https://www.msn.com/en-us/technology/biotechnology/medtronic-is-seeking-us-clearance-to-use-its-hugo-surgical-robot-in-far-more-operations/ar-AA26K7iS)
7. [MD+DI (Omar Ford), "Intuitive's Cardiac Push Challenges Medtronic, J&J Rivals", 29 September 2026](https://www.mddionline.com/robotics/intuitive-s-cardiac-push-challenges-medtronic-j-j-rivals)
8. [MassDevice, "Intuitive receives CE mark for da Vinci 5 cardiac, heart surgery procedures", collected 5 October 2026](https://www.massdevice.com/intuitive-receives-ce-mark-da-vinci-5-cardiac-heart-surgery-procedures/)
9. [The Motley Fool (Joe Tenebruso), "Why Intuitive Surgical Stock Dropped This Week", 18 July 2026](https://www.fool.com/investing/2026/07/18/why-intuitive-surgical-stock-dropped-this-week/)
10. [Simply Wall St via Yahoo Finance, "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders", 10 August 2026](https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-ottava-fda-002047054.html)


---

Intuitive Surgical is 35% off its high as a court, J&J and Medtronic test its robot monopoly — The Inference. Canonical: https://theinference.org/article/three-fronts-one-earnings-date-intuitive-s-robot-monopoly-gets-tested
